Proactive Investors Australia | CELLMID LIMITED : Key European Patent for Anti-Midkine Antibodies Granted 4-traders (press release) The granted claims cover Cellmid's cancer program for antibodies and antibody fragments which bind to the important functional C-domain of growth factor midkine (MK). In particular, antibodies of any kind that bind to key MK C-domain epitopes are covered. Cellmid awarded key European midkine antibodies patent, covers cancer and ... Cellmid, Key European Patent for Anti-Midkine Antibodies Granted |
